Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nexium-Style Products Encourage Price Competition, FDA’s McClellan Says

Executive Summary

The availability of follow-on products like AstraZeneca's Nexium can encourage price competition within a therapeutic class, FDA Commissioner McClellan told the National Press Club Aug. 8 in Washington, D.C

You may also be interested in...



Nexium DTC Ads Criticized By CMS’ Scully During Medicaid Hearing

Direct-to-consumer advertising for follow-on drugs such as AstraZeneca's Nexium are part of the reason for "huge" Medicaid spending on prescription drugs, Centers for Medicare & Medicaid Services Administrator Thomas Scully told a House Energy & Commerce/Health Subcommittee hearing Oct. 8

Nexium DTC Ads Criticized By CMS’ Scully During Medicaid Hearing

Direct-to-consumer advertising for follow-on drugs such as AstraZeneca's Nexium are part of the reason for "huge" Medicaid spending on prescription drugs, Centers for Medicare & Medicaid Services Administrator Thomas Scully told a House Energy & Commerce/Health Subcommittee hearing Oct. 8

Mylan Launches Generic Omeprazole; Takes Risk For Purple Gold

Mylan's decision to launch the second generic version of AstraZeneca's Prilosec (omeprazole) could inject a new level of price competition into the proton pump inhibitor category

Related Content

UsernamePublicRestriction

Register

PS042327

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel